Articles & Video
PharmAI – Industry is Smartening Up to Potential of Artificial Intelligence
Artificial Intelligence (AI) has enormous potential in changing the delivery of health care and improving patient outcomes, with applications in pattern detection, patient monitoring, disease diagnosis and treatment selection. The rationale is that AI can be used to enhance the decision-making process, taking into account far more data than are available to physicians via conventional means.
Tracking the Power of Presenting at Biotech Showcase
For the first time, Informa Pharma Intelligence explores the achievements by Biotech Showcase presenting companies, delving into the deal-making activity that has occurred for companies who have presented at the conference in the last five years.
Networking your way to the top, whether in North Face or Brooks Brothers
Timmerman selected Mount Kilimanjaro, a more achievable trek for most climbers, for his next philanthropic adventure, and invited members of the biotech community and employees of Fred Hutch to join him. On January 14, 2019, Timmerman will do a presentation on the Climb to Fight Cancer at Biotech Showcase™, from 4:15–5 pm, at the Parc 55 San Francisco Hotel.
The Power of Presenting at Biotech Showcase
Informa Pharma Intelligence analysts took a deep dive into what has happened to companies who have presented at Biotech Showcase. Since 2015, over 250 companies that have presented at Biotech Showcase have generated deals worth over $61bn.
Giving a Pharma Giant a Tech Startup Makeover
This shows how we’re using data and digital to reimagining medicine. If successful, this could open up the entire area of digital therapeutics.
Biotech VC Down 20% in US as Policies Drive Away Foreign Investors, BIO Says
Reforms to a US national security regulation are putting off foreign investors and driving down VC investment in the biotech space by as much as 20 percent, says BIO’s David Thomas.
Investor Survey: US Leads Global Healthcare Innovation, but China to Catch Up by 2025
According to a survey of 53 China-focused life science investors, 79% of the respondents believe the US is the current global leader in innovation for life science while only 15% picked China. But fast forward six years to expectations for 2025, the vote was split evenly between the two countries at about 48% each, a big turnaround.
How sea turtles are essential to success in China
Recent changes in the Chinese regulatory and legal systems have transformed the Chinese life science market. This BIO-Europe panel on “The China Market” covered a lot of territory discussing the market, clinical trials, sophisticated business models, novel science, and the importance of “sea turtles.”
Antimicrobial resistance: Workable business models for AMR innovation
Many antibiotics are no longer effective. Every year, an estimated 33,000 people die from resistant agents in the EU. More and more multiresistant strains arise across the globe and the list of last resort antibiotics gets smaller, which is why the United Nations has named antibiotic resistance the "biggest and most urgent global health threat."
Moment of truth: Term sheet negotiations reveal more than you might expect
The thought of negotiating the terms and conditions for a partnership with a pharma company or other third party is often full of ambiguity or anxiety for biotech innovators and executives. But when approached with the right mindset, the process can provide critical insights while smoothing the way for contract negotiations down the road.
New players to step into the AMR field
Despite challenging market conditions public and private stakeholders around the globe show promising action to advance drug development in the fight against antimicrobial resistance. Even new players are entering the field.
Digital Health: Advancing innovation through technology and strategic partnerships
Insights from investors, biopharma leaders and digital health executives on how to navigate the digital health sector as it transforms every aspect of the pharmaceutical value chain.
Pharma embraces biopartnering at BIO-Europe to address its innovation deficit
Big pharma’s appetite for early preclinical assets continues to grow and now represents the development phase with the most deals and largest total deal value. Consequently, an increasing number of academic institutions are taking the opportunity to showcase their efforts in the academic track at BIO-Europe.
BIO-Europe® 2019: Life sciences companies follow the footsteps of Hamburg’s ancient merchants as they gather to celebrate innovation and partnership
BIO-Europe, now celebrating 25 years of facilitating partnerships that drive life science dealmaking, is the perfect stage for budding biotech and pharmaceutical companies to meet and engage with delegates from all parts of the life sciences value chain.
Just do it. Nike showcases Barcelona’s Startup Slam winner
What are the winners of the past BIO-Europe Spring and BIO-Europe's Startup Slam doing? Catch up with some of them and their most recent successes. Starting with Peptomyc’s co-founders Laura Soucek and Marie-Eve Beaulieu.
Traditional and Non-Traditional Epidemiology: The Sum is Greater than the Value of its Parts
Understand the current state of your market and ensure you are investing in solutions that are right for your business priorities.
Continental Shift: 25 Years of European Biotech Trends and New e-book
Explore the major milestones of European biotech. Learn how European biotech emerged from the US shadow, what key events shaped the industry, and how the sector is expected to develop in the forthcoming years.